PGI2 restrains immunopathogenesis in hypertension
PGI2 抑制高血压的免疫发病机制
基本信息
- 批准号:10282751
- 负责人:
- 金额:$ 13.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-15 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adaptive Immune SystemAddressAdultAffectAllergic inflammationAmericanAngiotensin IIAnti-Inflammatory AgentsAntigen PresentationAntigensAortaArachidonic AcidsAwardBiological AvailabilityBlood PressureCardiovascular DiseasesCardiovascular systemCell physiologyCellsCyclooxygenase InhibitorsDataDendritic CellsDevelopmentDevelopment PlansDiseaseDisease ProgressionDisease modelEnvironmentEnzymesEpoprostenolEtiologyExperimental ModelsFDA approvedFoundationsGene Expression ProfileHumanHypertensionImmuneImmune responseImmune systemImpairmentIndividualInflammationInflammatoryInflammatory ResponseInfusion proceduresInvadedJournalsKidneyKnockout MiceLaboratoriesLeadLipidsMentorsMetabolic PathwayModelingMorbidity - disease rateMusOrganPTGS2 genePathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhasePhenotypePlayProductionPropertyProstaglandin ReceptorProstaglandinsPublicationsPulmonary HypertensionRegulatory T-LymphocyteResearchResearch PersonnelRoleSignal PathwaySignal TransductionSiteStimulusT-LymphocyteT-Lymphocyte SubsetsTestingTh1 CellsTh2 CellsTherapeuticThromboxanesTrainingTreprostinilTumor-infiltrating immune cellsUnited StatesVascular DiseasesVasoconstrictor AgentsWild Type Mouseanalogblood pressure regulationcareercareer developmentcell typeclinical investigationclinically significantcyclooxygenase 2cytokineeicosanoid metabolismhigh salt diethypertension controlhypertension treatmentimmune functionimmunoregulationinhibitor/antagonistkidney vascular structuremacrophagemonocytemortalitymouse modelnormotensivenovelnovel therapeuticspreventprogramsreceptorresponsetranscriptome sequencingvascular inflammation
项目摘要
PROJECT SUMMARY
Hypertension is a disease defined as blood pressure that is greater than 130/80mmHg. Hypertension
contributes significantly to cardiovascular disease morbidity and mortality. While the importance of blood
pressure control has become abundantly clear, we are still far from understanding the true etiology of
hypertension. In recent years, inflammation was determined to play a causal role in hypertension. Specifically,
immune cells invade target organs during the course of the disease and release cytokines that cause end-
organ damage. Several studies have determined antigen presentation by dendritic cells (DCs) and monocytes
is important for initiation of hypertension. In addition, pro-inflammatory T cells perpetuate the disease. Anti-
inflammatory T regulatory cells (Treg) can control the hypertensive response. Interestingly, evidence suggests
that long-lasting use of cyclooxygenase inhibitors, which prevent metabolism of arachidonic acid (AA) to
prostaglandins and thromboxane, increases blood pressure. Prostaglandin I2 (PGI2) is an AA metabolite that
our laboratory has determined has immunomodulatory effects. Our group has demonstrated that PGI2 acts to
directly inhibit the functionality of pro-inflammatory DCs and CD4+ Th1 and Th2 cells, while promoting the
function of tolerogenic DCs. However, the impact of PGI2 on the functionality of immune cells in hypertension is
unknown. A previous study has demonstrated that mice deficient in the receptor for PGI2, IP, develop elevated
blood pressure in response to high salt diet, suggesting that PGI2 signaling is important for controlling blood
pressure elevation in response to stimuli. Further, I have preliminary data which suggests that PGI2 controls
the inflammatory response to hypertensive stimuli. Specifically, mice deficient in IP have increased infiltration
of T cells into their aortas compared to wild-type (WT) mice in response to angiotensin II (Ang II). In addition,
infusion of the PGI2 analog treprostinil during the course of Ang II infusion prevents the infiltration of T cells,
monocytes/macrophages and DCs into the aorta of WT mice compared to WT mice that received Ang II and
the vehicle for treprostinil. Thus, these recent studies and my preliminary data lead me to hypothesize
that PGI2 promotes anti-inflammatory responses during hypertension. To test this hypothesis we will use
mouse models of hypertension and primary cells from normotensive and hypertensive mice and humans to:
Aim 1 (K99): Test the hypothesis that PGI2 promotes Treg function and stability during hypertension,
thereby counteracting pro-inflammatory subsets of T cells; and Aim 2 (R00): Test the hypothesis that
PGI2 restrains pro-inflammatory DC and promotes tolerogenic DC function during hypertension.
Determining the mechanisms by which PGI2 controls the immune response to hypertension will greatly
advance the field and result in new therapeutic directions for the treatment of hypertension. These proposed
studies, along with my proposed career development plan, will provide a foundation for my career as an
independent investigator in an outstanding environment.
项目摘要
高血压是一种疾病,定义为血压大于130/80 mmHg。高血压
心血管疾病的发病率和死亡率。虽然血液的重要性
压力控制已经变得非常清楚,我们仍然远远没有了解真正的病因,
高血压近年来,炎症被确定为在高血压中起因果作用。具体地说,
免疫细胞在疾病过程中侵入靶器官并释放细胞因子,
器官损伤一些研究已经确定了树突状细胞(DC)和单核细胞的抗原呈递
是引发高血压的重要因素。此外,促炎性T细胞使疾病永久化。反
炎症性T调节细胞(Treg)可以控制高血压反应。有趣的是,证据表明
长期使用环氧合酶抑制剂,其防止花生四烯酸(AA)代谢,
前列腺素和血栓素,增加血压。前列腺素I2(PGI 2)是AA代谢物,
我们的实验室已经确定它具有免疫调节作用。我们的研究小组已经证明,PGI 2的行为,
直接抑制促炎DC和CD 4 + Th 1和Th 2细胞的功能,同时促进
致耐受性DC的功能。然而,PGI 2对高血压患者免疫细胞功能的影响,
未知先前的研究表明,PGI 2受体IP缺陷的小鼠,
高盐饮食对血压的影响,表明PGI 2信号对控制血压很重要。
对刺激作出反应的压力升高。此外,我有初步的数据表明,PGI 2控制
对高血压刺激的炎症反应。具体而言,IP缺陷的小鼠具有增加的浸润,
与野生型(WT)小鼠相比,T细胞进入它们的睾丸,对血管紧张素II(Ang II)的反应。此外,本发明还提供了一种方法,
在Ang II输注过程中输注PGI 2类似物曲前列环素防止T细胞的浸润,
与接受Ang II的WT小鼠相比,单核细胞/巨噬细胞和DC进入WT小鼠的主动脉,
曲前列环素的载体。因此,这些最近的研究和我的初步数据使我假设,
PGI 2在高血压期间促进抗炎反应。为了验证这一假设,我们将使用
高血压小鼠模型和来自血压正常和高血压小鼠和人的原代细胞:
目的1(K99):检验PGI 2在高血压期间促进Treg功能和稳定性的假设,
从而抵消T细胞的促炎亚群;以及目标2(R 00):检验以下假设:
PGI 2抑制促炎性DC并促进高血压期间致耐受性DC功能。
确定PGI 2控制高血压免疫反应的机制将大大有助于
推进该领域,并为高血压的治疗提供新的治疗方向。这些拟议
学习,沿着我的职业发展计划,将为我的职业生涯提供一个基础,
独立调查员在出色的环境。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Allison Elizabeth Norlander其他文献
Allison Elizabeth Norlander的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Allison Elizabeth Norlander', 18)}}的其他基金
PGI2 restrains immunopathogenesis in hypertension
PGI2 抑制高血压的免疫发病机制
- 批准号:
10731402 - 财政年份:2023
- 资助金额:
$ 13.8万 - 项目类别:
PGI2 restrains immunopathogenesis in hypertension
PGI2 抑制高血压的免疫发病机制
- 批准号:
10447208 - 财政年份:2021
- 资助金额:
$ 13.8万 - 项目类别:
The Effect of Salt on T Cell Function in Hypertension
盐对高血压患者 T 细胞功能的影响
- 批准号:
9138616 - 财政年份:2015
- 资助金额:
$ 13.8万 - 项目类别:
The Effect of Salt on T Cell Function in Hypertension
盐对高血压患者 T 细胞功能的影响
- 批准号:
8908297 - 财政年份:2015
- 资助金额:
$ 13.8万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 13.8万 - 项目类别:
Research Grant